Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study

INTRODUCTION: Epigenetic modifications play an important role in progression and development of resistance in (V600E)BRAF positive metastatic melanoma. Therefore, we hypothesized that the action of vemurafenib (BRAF inhibitor) can be made more effective by combining with low dose decitabine (a DNA m...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Zakharia, Yousef, Monga, Varun, Swami, Umang, Bossler, Aaron D., Freesmeier, Michele, Frees, Melanie, Khan, Mirza, Frydenlund, Noah, Srikantha, Rithu, Vanneste, Marion, Henry, Michael, Milhem, Mohammed
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Clinical Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5687680/
https://ncbi.nlm.nih.gov/pubmed/29179510
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21269
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados